Targeted agents for the treatment of advanced renal cell carcinoma

102Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Metastatic renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies. However, the elucidation of the molecular mechanisms underlying RCC development has led to the identification of promising targets for novel therapeutic agents. The involvement of the Von Hippel-Lindau protein pathway in clear cell RCC suggests that downstream targets of this pathway, namely, signaling through vascular endothelial growth factor (VEGF) in endothelial cells, platelet-derived growth factor (PDGF) in endothelial cells and pericytes, and the epidermal growth factor receptor (EGFR) pathway in tumor cells are all reasonable and rational therapeutic targets. A number of agents are in development that target VEGF (bevacizumab, a recombinant, humanized monoclonal antibody) or its receptor, VEGFR (PTK787, SU011248, and BAY 43-9006, all of which are small molecule inhibitors). Agents targeting EGFR also are being investigated clinically (gefitinib, cetuximab, erlotinib, and ABX-EGF). The Raf/MEK/ERK pathway is an important downstream convergence point for signaling through VEGFR, platelet-derived growth factor receptor (PDGFR), and EGFR (all have receptor tyrosine kinase activity) and also has important antiapoptotic effects, thereby providing an attractive target for intervention. In addition to inhibiting VEGFR and PDGFR-mediated angiogenic pathways, BAY 43-9006 has been shown to inhibit the Raf/MEK/ERK pathway at the level of Raf kinase. MEK-directed therapeutic approaches are also in development. Given that multiple molecular pathways are implicated in tumor cell growth, antitumor activity may be increased by using individual agents that target multiple pathways, or by combining different agents to allow vertical or horizontal inhibition of relevant pathways. © 2005 American Cancer Society.

References Powered by Scopus

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

9687Citations
N/AReaders
Get full text

Mutation and cancer: statistical study of retinoblastoma.

6080Citations
N/AReaders
Get full text

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

4330Citations
N/AReaders
Get full text

Cited by Powered by Scopus

ROS and ROS-Mediated Cellular Signaling

1540Citations
N/AReaders
Get full text

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

1234Citations
N/AReaders
Get full text

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review

830Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Stadler, W. M. (2005, December 1). Targeted agents for the treatment of advanced renal cell carcinoma. Cancer. https://doi.org/10.1002/cncr.21453

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

69%

Professor / Associate Prof. 3

19%

Researcher 2

13%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

55%

Agricultural and Biological Sciences 5

25%

Biochemistry, Genetics and Molecular Bi... 3

15%

Computer Science 1

5%

Save time finding and organizing research with Mendeley

Sign up for free